Combination of NK cells therapy and oral administration of entinostat as an approach for osteosarcoma lung metastasis treatment by Simin Kiany et al.
POSTER PRESENTATION Open Access
Combination of NK cells therapy and oral
administration of entinostat as an approach for
osteosarcoma lung metastasis treatment
Simin Kiany*, Ling Yu, Eugenie S Kleinerman
From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
National Harbor, MD, USA. 4-8 November 2015
Introduction
The goal of this study is to find an alternate therapy for
osteosarcoma (OS) lung metastasis. Previously we showed
that NK cell therapy significantly decreased OS lung
metastasis in a mouse model; however, the therapy was
not effective enough to cure OS lung metastasis. To
augment the NK cell therapy, we elected to combine it
with entinostat, an HDAC inhibitor. Studies have shown
that HDACis sensitize tumor cells to NK cells cytotoxicity
mostly by increasing expression of ligands for NK cells on
tumor cells.
Methods
Flow cytometry, western blot and Q-PCR were used to
investigate whether entinostat increased expression of NK
cell ligands on OS cells. Effects of entinostat on NK cell
viability, receptor expression, and cytotoxicity were
explored using, a viability test, flow cytometry, and calcein
release assay, respectively. NK cells were isolated from
blood buffy coats and were expanded ex vivo for 4 weeks
using genetically engineered K562 cells and human IL-2.
Q-PCR was used to measure microRNAs expression in
OS cells. Ten, 5, or 2.5 mg/kg of entinostat were orally
administered to mice to determine the sub-therapeutic
dose of the drug for in vivo study.
Results
We demonstrated that 2 μM entinostat for 48 h up-
regulated expression of NK cell ligands (ULBP1, ULBP2/
5/6, MIC A/B, and CD155) on OS cell lines (LM7, KRIB,
CCHOSD, and CCHOSO). In addition, entinostat treat-
ment increased susceptibility of OS cell lines to NK cell
cytotoxicity. NK cell treatment with up to 2 μM entinostat
did not neither affect the viability of NK cells nor expres-
sion of NK cell receptors (NKG2D, NKp30, NKp44,
NKp46, and DNAM-1). NK cells pre-treatment with
entinostat for 24 h did not decrease cytotoxicity of NK cell
to OS cell lines. We also showed that entinostat increased
MICA/B expression on OS cells by down-regulating
miR-20a, miR-93, and mir-106b expression. We demon-
strated that the sub-therapeutic dose of entinostat that
significantly increased MICA/B on OS lung metastasis was
5mg/kg three times a week for 5 weeks.
Conclusions
We demonstrated that entinostat immunosensitized OS
cells to NK cell lysis by inducing up-regulation of ligands
for NK cells on OS cells. Our results suggest that NK cell
therapy in combination with entinostat is an innovative
approach to enhance the immunotherapeutic effect of NK
cells against osteosarcoma pulmonary metastases.
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